Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
نویسندگان
چکیده
منابع مشابه
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF). Fifty-eight subjects had ≥1 non-driver mutation upon diagnosis. Mutations in mRNA splicing genes, especially in U2A...
متن کاملCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
The recent approval of molecular-targeted therapies for myeloproliferative neoplasm-associated myelofibrosis (MPN-MF) has dramatically changed its therapeutic landscape. Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF, especially those with disease-related splenomegaly, intermediate- or high-risk disease, and const...
متن کاملBenefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-term outcomes and correlations with mutational patterns of driver and non-driver mutations analyze...
متن کاملIncreased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.
Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0-33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of genetic predisposing factors. We identified 22 patients with myeloproliferative neoplasm who developed lymphoid neoplasm over their lifetime. We...
متن کاملPathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm
In the diagnostic criteria of these neoplasms, besides haematological tests and osteomedular biopsy an important role is played by the JAK2V617F, CALR and Mpl mutational status testing.1 Numerous researches involved the presence of JAK mutation in increasing the risk of thrombosis; in this way, along with advanced age and history of thrombosis in the classification criteria in “high risk” forms...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2020
ISSN: 0887-6924,1476-5551
DOI: 10.1038/s41375-020-0954-2